Two patents currently held, every record listed here
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2038. from the record
Of the 2 now held by other companies, 2 name City of Hope as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2038
Next term end
2
Patent families
When these terms end
Each bar runs from grant to computed term end. 2018 to 2038.
US 11,560,395
Azithromycin Derivatives Containing a Phosphonium Ion as Anticancer Agents
Aug 28, 2038
US 11,427,606
Azithromycin Derivatives Containing a Phosphonium Ion as Anticancer Agents
Sep 3, 2038
20222026203020342038
Every computed term in this portfolio is shown above.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Aug 2038 · High confidence
Also notable
Ends Sep 2038 · High confidence
Azithromycin Derivatives Containing a Phosphonium Ion as Anticancer Agents
US 11,560,395
Granted 2023. Computed term ends 2038.
Azithromycin Derivatives Containing a Phosphonium Ion as Anticancer Agents
US 11,427,606
Granted 2022. Computed term ends 2038.
Formerly held, still cited
Notable
Ends Feb 2036 · High confidence
The most cited patent in this portfolio, cited by 18 later US patents, top 25% of utility patents granted in 2018 in our data. Protection runs to 2036.
now held by City of Hope
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Azithromycin Derivatives Containing a Phosphonium Ion as Anticancer Agents (2019) | 1 in force | to Sep 2038 |
| Azithromycin Derivatives Containing a Phosphonium Ion as Anticancer Agents (2019) | 1 in force | to Aug 2038 |
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,560,395 | Azithromycin Derivatives Containing a Phosphonium Ion as Anticancer Agents In force · High confidence | In force | High confidence | |
| US 11,427,606 | Azithromycin Derivatives Containing a Phosphonium Ion as Anticancer Agents In force · High confidence | In force | High confidence |
Also on record, not counted in the 2: 2 patents in force now held by others · 1 patent ended · 1 application abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.